Moleculin Biotech Enters Material Definitive Agreement

TL;DR

Moleculin Biotech just signed a big deal, details to come.

AI Summary

On December 21, 2025, Moleculin Biotech, Inc. entered into a material definitive agreement. The company, headquartered in Houston, TX, filed an 8-K report detailing this event. Specific details of the agreement, including parties involved and financial terms, are not fully disclosed in the provided excerpt.

Why It Matters

This filing indicates a significant business development for Moleculin Biotech, potentially impacting its future operations and financial standing.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on the undisclosed terms.

Key Players & Entities

• Moleculin Biotech, Inc. (company) — Registrant
• December 21, 2025 (date) — Date of earliest event reported
• 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
• 713-300-5160 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $3.90 — e the exercise price of the Warrants to $3.90 per share; and (B) the Series E warrant
• $2.5 million — that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the C
• $6.8 million — transaction pursuant to which it raised $6.8 million in gross proceeds from the exercise of
• $1.1 million — raised gross proceeds of approximately $1.1 million at an average price of approximately $8
• $8.31 — on at an average price of approximately $8.31 per share pursuant to its at-the-market
• $26.9 million — Company had a stockholders' deficit of $26.9 million. As of the date hereof, after managemen
• $10.0 million — 's stockholders' equity is in excess of $10.0 million. Item 9.01 Financial Statements and

Filing Documents

• mbrx20251221_8k.htm (8-K) — 33KB
• ex_901475.htm (EX-4.1) — 138KB
• ex_901476.htm (EX-4.2) — 147KB
• ex_901551.htm (EX-4.3) — 140KB
• ex_901477.htm (EX-10.1) — 31KB
• logosm01.jpg (GRAPHIC) — 6KB
• 0001437749-25-038478.txt ( ) — 734KB
• mbrx-20251221.xsd (EX-101.SCH) — 3KB
• mbrx-20251221_def.xml (EX-101.DEF) — 11KB
• mbrx-20251221_lab.xml (EX-101.LAB) — 15KB
• mbrx-20251221_pre.xml (EX-101.PRE) — 11KB
• mbrx20251221_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement. On December 21, 2025, Moleculin Biotech, Inc. (the "Company") entered into separate warrant amendment agreements (collectively, the "Warrant Amendment") with the holders of the Company's Series E warrants (the "Series E warrants"), Series F warrants (the "Series F warrants"), and Series G warrants (the "Series G warrants," and collectively with the Series E warrants and Series F warrants, the "Warrants"). Pursuant to the Warrant Amendment, (A) the Warrants were amended to reduce the exercise price of the Warrants to $3.90 per share; and (B) the Series E warrants and Series F warrants were amended to delete the following sections immediately following the foregoing repricing: (i) a provision providing for the adjustment of the exercise price (and with respect to the Series E warrants, the number of shares issuable thereunder) of the Series E warrants and Series F warrants if the Company changes the exercise or conversion price of any outstanding convertible securities to a price per share less than the exercise price of the Series E warrants and Series F warrants then in effect; and (ii) a provision providing for the adjustment of the exercise price (and with respect to the Series E warrants, the number of shares issuable thereunder) of the Series E warrants and Series F warrants if the price of the Company's common stock after the completion of a share split, share dividend, share combination, recapitalization or other similar transaction is less than the exercise price of the Series E warrants and Series F warrants then in effect. In addition, the Warrant Amendment modified the definition of Black Scholes Value in the Series E warrants and Series F warrants. The foregoing description of the form of Warrant Amendment, the amended and restated Series E warrant, the amended and restated Series F warrant and the amended and restated Series G warrant is not complete and each is qualified in its entirety by refer

01

Item 8.01 Other Events. As previously disclosed, on May 23, 2025, the Company received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which notified the Company that it did not comply with Nasdaq's Listing Rule 5550(b)(1) (the "Listing Rule"), which requires that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the Company also did not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Staff had previously granted the Company an extension until November 19, 2025 to regain compliance with the Listing Rule. On November 20, 2025, the Company received a delist determination letter from the Staff (the "Nasdaq Notice") advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule. Accordingly, the Staff indicated that unless the Company requested a hearing panel (a "Panel") appeal of the delist determination its securities would be delisted. The Company appealed Nasdaq's determination to a Panel, which stayed any suspension or delisting pending the Panel's determination and any further extension the Panel may grant. The Panel hearing is currently scheduled for January 20, 2026. Subsequent to the receipt of the Nasdaq Notice, the Company has undertaken the following steps to come into compliance with the Listing Rule: (i) on December 9, 2025, the Company completed a warrant inducement transaction pursuant to which it raised $6.8 million in gross proceeds from the exercise of warrants; (ii) the Company raised gross proceeds of approximately $1.1 million at an average price of approximately $8.31 per share pursuant to its at-the-market facility; and (iii) on December 21, 2025, the Company entered into the Warrant Amendment described in Item 1.01 of this Form 8-K with the holders of certain of its Series E warrants and Series F

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . 4.1 Form of Amended and Restated Series E Warrant 4.2 Form of Amended and Restated Series F Warrant 4.3 Form of Amended and Restated Series G Warrant 10.1 Form of Warrant Amendment 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: December 22, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR